POLE c.1801G>A ;(p.D601N)

Variant ID: 12-133245519-C-T

NM_006231.2(POLE):c.1801G>A;(p.D601N)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With BAP1-Frame Shift Mutation: Case Report and Literature Review.

Frontiers In Oncology
Lian, Bi-Jun BJ; Zhang, Ke K; Fang, Xu-Dong XD; Li, Feng F; Dai, Zhao Z; Chen, Wei-Ying WY; Qi, Xiao-Ping XP
Publication Date: 2022

Variant appearance in text: POLE: 1801G>A; D601N
PubMed Link: 35875073
Variant Present in the following documents:
  • DataSheet_1.xlsx, sheet 1
View BVdb publication page



Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2- Breast Cancer Patient With High Tumor Mutational Burden.

Frontiers In Oncology
Wang, Rong R; Yang, Yuchen Y; Ye, Wei-Wu WW; Xiang, Jianxing J; Chen, Songan S; Zou, Wei-Bin WB; Wang, Xiao-Jia XJ; Chen, Tianhui T; Cao, Wen-Ming WM
Publication Date: 2020

Variant appearance in text: POLE: 1801G>A; Asp601Asn
PubMed Link: 33634015
Variant Present in the following documents:
  • Table_1.xlsx, sheet 8
View BVdb publication page